A study investigating subjects across the aging and AD spectrum using PET imaging for microglial activation and tau pathology found that cerebrospinal fluid sTREM2, along with [C11]PBR28 PET imaging, may serve as an indicator of in vivo microglial activation. This evidence concerns the gene MAPT and Alzheimer disease.